Wexamined and sampled 45 patients with toe-web intertrigo for bacteriological and mycological studies. Prominent isolated pathogens were the genus Candida [57.7%], genus Aspergillus [28.8%], Pseudomonas aeruginosa [26.7%] and coliforms [24.4%]. Dermatophytes scored 4.4% [Trichophyton rubrum]. There were 43 patents [95.5%] who presented with marked hyperkeratosis and maceration of the toe-webs involved. The tradition of the Emirati population of sitting cross-legged may, over time, induce in the toe-webs of overweight individuals a macerated pressure-reaction hyperkeratosis that is colonized by environmental germs. T. rubrum and T. mentagrophytes are uncommon in the Al-Ain environment and this may explain the rarity of dermatophytes in toe-web intertrigo in our study.
A609probabilistic sensitivity analysis suggests that at willingness-to-pay threshold of £20-£30,000 per quality-adjusted life year, the probability of early treatment being cost-effective is 60%. ConClusions: Panretinal photocoagulation administered at the severe NPDR stage is likely to be cost-effective. However, given the limitations of the evidence on current treatments, these results to be interpreted with caution. A trial of early versus deferred laser therapy is needed to provide better data based on modern treatments.objeCtives: CUA of cryosurgery, topical treatments (diclofenac 3% 12 weeks, imiquimod 3.75% 6 weeks or 5% 4/8 weeks, ingenol mebutate gel (IMG) 0.015%/ head 3 days or 0.05%/body 2 days), and methyl aminolevulinate + photodynamic therapy (MAL+PDT) in the treatment of 25cm 2 AK-plague affecting any body part. Methods: A sequential probabilistic decision-tree with 2-year time-horizon was used to assess the cost-utility (incremental cost-effectiveness ratio, ICER) of AK-treatments, and to determine the cost-effectiveness acceptability frontier (CEAF) and expected value of perfect information per patient (EVPI) from health care payer perspective. In the model, the first-line AK-treatment resulted in complete clearance (CC) with or without adverse events (AE), non-CC or AK-recurrence. Non-CC AK was retreated with PDT and AK-recurrence was retreated with the previous treatment. Incident AK-patients (year 2009, n= 3409, organ transplant patients excluded) were identified from the Finnish hospital discharge register to assess AK-related 2-year secondary health care costs for patients initiating different treatment regimens. Other costs included general practitioner, AE-management, and outpatient drugs (5/2014 without VAT; other costs in 2013 value). Quality-adjusted life-years (QALY) were based on EQ-5D. Results were discounted with 3% annually. Results: The mean per patient 2-year QALYs (costs) were 1.519 (€ 727) for IMG 0.015%, 1.518 (€ 887) for MAL+PDT, 1.516 (€ 802) for IMG 0.05%, 1.514 (€ 995) for diclofenac, 1.512 (€ 815) for imiquimod 3.75%, 1.511 (€ 707) for imiquimod 5%, and 1.507 (€ 1010) for cryosurgery. IMG 0.015% had € 2806/QALY gained ICER against imiquimod 5%, and dominated other AK-treatments. IMG 0.05% dominated diclofenac, imiquimod 3.75% and cryosurgery, and had € 21,550/QALY gained ICER against imiquimod 5%. MAL+PDT had € 32,848/QALY gained ICER against IMG 0.05%. Based on the CEAF, IMG 0.015% was the optimal treatment when willingness-to-pay/QALY gained exceeded € 2806. The EVPI was € 25/€ 81/€ 211 with the willingness-to-pay of € 0/€ 15,000/€ 30,000 per QALY gained. ConClusions: IMG 0.015% was the most cost-effective first-line AK-treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.